Ocrelizumab dose selection for treatment of pediatric relapsing–remitting multiple sclerosis: results of the OPERETTA I study

Background The presented study identified the appropriate ocrelizumab dosing regimen for patients with pediatric-onset multiple sclerosis (POMS). Methods Patients with POMS aged 10–17 years were enrolled into cohort 1 (body weight [BW] 

Saved in:
Bibliographic Details
Published in:Journal of neurology 2025-02, Vol.272 (2), p.137, Article 137
Main Authors: Mar, Soe, Valeriani, Massimiliano, Steinborn, Barbara, Schreiner, Teri, Waubant, Emmanuelle, Filippi, Massimo, Kotulska, Katarzyna, Mazurkiewicz-Beldzinska, Maria, El Azzouzi, Bouchra, Lin, Chien-Ju, Shen, Yun-An, Kletzl, Heidemarie, Evershed, Joanna, Hogea, Alexandra, Manlius, Corinne, Bonati, Ulrike, Banwell, Brenda
Format: Article
Language:English
Subjects:
Adolescent
Antibodies, Monoclonal, Humanized - administration & dosage
Antibodies, Monoclonal, Humanized - adverse effects
Antibodies, Monoclonal, Humanized - pharmacokinetics
Antibodies, Monoclonal, Humanized - pharmacology
Body weight
CD19 antigen
Child
Cohort Studies
Dosage
Dose-Response Relationship, Drug
Exploratory behavior
Female
Humans
Immunologic Factors - administration & dosage
Immunologic Factors - adverse effects
Immunologic Factors - pharmacokinetics
Immunologic Factors - pharmacology
Lymphocytes B
Male
Medicine
Medicine & Public Health
Monoclonal antibodies
Multiple sclerosis
Multiple Sclerosis, Relapsing-Remitting - drug therapy
Neurology
Neuroradiology
Neurosciences
Original Communication
Patients
Pediatrics
Pharmacodynamics
Pharmacokinetics
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background The presented study identified the appropriate ocrelizumab dosing regimen for patients with pediatric-onset multiple sclerosis (POMS). Methods Patients with POMS aged 10–17 years were enrolled into cohort 1 (body weight [BW] 
ISSN:0340-5354
1432-1459
1432-1459
DOI:10.1007/s00415-024-12879-z